Mr. Stan Lis reports

LEENLIFE PHARMA INTERNATIONAL CLOSES FINAL TRANCHE OF PRIVATE PLACEMENT

LeenLife Pharma International Inc. has closed the final tranche of a non-brokered private placement offering of units previously announced on Dec. 14, 2016, and Jan. 6, 2017.

The closing of the final tranche resulted in gross proceeds to the company of $473,000 from the sale of 4.73 million units of the company. The proceeds realized from the final tranche will be used for general corporate and working capital purposes.

Each unit was sold at a price of 10 cents and consists of one common share of the company and one common share purchase warrant. Each warrant will be exercisable into one common share at a price of 15 cents per common share for a period of two years from closing of the final tranche.

In total under the private placement, the company issued 14,515,000 units for aggregate gross proceeds of $1,451,500. Certain registered brokers were paid a cash fee equal to 9 per cent of the gross proceeds they raised under the first and second tranches of the private placement. All securities issued under the final tranche are subject to a statutory hold period of four months and one day from the distribution date.

About LeenLife Pharma International Inc.

LeenLife has acquired a proprietary process to isolate omega-3 fatty acids from flaxseeds. LeenLife products have been developed and researched for over 17 years.

We seek Safe Harbor.